EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin

Emma Poole, Sarah A Hosgood, Erica Appiah, Elizabeth Elder, Samuel Moulding, Fredrika Carlsson, Anna K Drzazga, Mette M Rosenkilde, Johan Lantto, Ian McGowan, Thomas Kledal, Michael L Nicholson und 1 weitere

American Journal of Transplantation · 2026

DOI: 10.1016/j.ajt.2026.02.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Transplantation, 2026. Verfasst von Emma Poole und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. Electronic address: elp27@cam.ac.uk. Hauptthemen laut MEDLINE: Cytomegalovirus, Cytomegalovirus Infections, Kidney, Virus Activation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Medical Research Foundation, Newcastle University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human cytomegalovirus (HCMV) is a ubiquitous pathogen that establishes latent infections, with no accompanying disease. However, during immune suppression, eg, during organ transplantation, the virus can reactivate and cause serious morbidity. SYN002 is a chemokine-based immunotoxin targeting HCMV protein "Unique Short 28," a virally encoded receptor expressed on both latently and lytically HCMV-infected cells. Following binding to and internalization through the HCMV protein "Unique Short 28," SYN002 induces apoptosis of the infected cell. The feasibility and safety of delivering SYN002 to human kidneys during normothermic machine perfusion to target HCMV were investigated. Cells from treated kidneys were isolated and analyzed in HCMV reactivation assays to quantify the latent viral reservoir. Perfusate parameters, perfusate, urine, and tissue samples were also collected for assessment of kidney function and injury. Administration of SYN002 significantly reduced the level of HCMV in kidneys, with no such decrease in control kidneys. There was no significant difference in perfusion parameters, urine output, injury markers, or histopathology between treated and control kidneys. SYN002 treatment during normothermic machine perfusion appeared safe and reduced HCMV levels in cells isolated from kidney perfusates. The study provides compelling proof-of-concept that SYN002 is efficacious and safe and that the use of SYN002 in this setting can be expected to provide clinical benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CytomegalovirusCytomegalovirus InfectionsKidneyVirus ActivationImmunotoxinsKidney TransplantationHumansPerfusion

Stichwörter der Autor:innen

human cytomegaloviruskidney perfusiontherapeutics

Substanzen

Immunotoxins

Autor:innen und Institutionen

  • Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. Electronic address: elp27@cam.ac.uk.
  • Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK; Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Division of Virology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
  • Synklino A/S, Frederiksborggade, Copenhagen, Denmark.
  • Department of Biomedical Sciences, University of Copenhagen, Laboratory for Molecular Pharmacology, Copenhagen, Denmark.

Förderung

  • National Institute for Health and Care Research
  • Medical Research Foundation
  • Newcastle University
  • UK Research and Innovation Medical Research Council
  • Kidney Research UK

Zitieren

APA

Poole, E., Hosgood, S. A., Appiah, E., Elder, E., Moulding, S., Carlsson, F., Drzazga, A. K., Rosenkilde, M. M., Lantto, J., McGowan, I., Kledal, T., Nicholson, M. L., & Sinclair, J. (2026). Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin. American Journal of Transplantation. https://doi.org/10.1016/j.ajt.2026.02.005

Vancouver

Poole E, Hosgood SA, Appiah E, Elder E, Moulding S, Carlsson F, et al. Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin. American Journal of Transplantation. 2026. doi:10.1016/j.ajt.2026.02.005

BibTeX
@article{Poole2026,
  author = {Poole, Emma and Hosgood, Sarah A and Appiah, Erica and Elder, Elizabeth and Moulding, Samuel and Carlsson, Fredrika and Drzazga, Anna K and Rosenkilde, Mette M and Lantto, Johan and McGowan, Ian and Kledal, Thomas and Nicholson, Michael L and Sinclair, John},
  title = {Inhibition of cytomegalovirus reactivation by ex vivo treatment of human kidneys with the SYN002 immunotoxin},
  journal = {American Journal of Transplantation},
  year = {2026},
  doi = {10.1016/j.ajt.2026.02.005}
}
Kostenlos starten →